Pozemet 15/500mg Tablet

Pozemet 15/500mg Tablet is a combination medication containing two active ingredients: Pioglitazone & Metformin. Pioglitazone HCI is an oral antidiabetic agent belonging to the thiazolidinedione class, while Metformin HCI is a biguanide antidiabetic drug. This combination tablet is designed to help manage blood sugar levels in individuals with type 2 diabetes mellitus.

Uses: Pozemet 15/500mg Tablet is used for the management of type 2 diabetes mellitus to:

1. Improve glycemic control: Both Pioglitazone HCI and Metformin HCI work synergistically to reduce blood glucose levels by different mechanisms of action.
2. Increase insulin sensitivity: Pioglitazone HCI enhances insulin sensitivity in peripheral tissues such as muscle and adipose tissue, thereby improving glucose utilization and decreasing insulin resistance.
3. Decrease hepatic glucose production: Metformin HCI primarily reduces hepatic glucose output by inhibiting gluconeogenesis and glycogenolysis, leading to decreased fasting blood sugar levels.
4. Lower HbA1c levels: The combination of Pioglitazone HCI and Metformin HCI helps lower glycated hemoglobin (HbA1c) levels, reflecting improved long-term glucose control.

Benefits:

• Dual action: Pozemet 15/500mg Tablet combines the complementary mechanisms of Pioglitazone HCI and Metformin HCI to target multiple aspects of glucose metabolism, resulting in improved glycemic control.
• Reduced insulin resistance: Pioglitazone HCI enhances insulin sensitivity, which can lead to better utilization of circulating insulin and improved glucose uptake by peripheral tissues.
• Lower cardiovascular risk: Pioglitazone HCI has been associated with potential cardiovascular benefits, including improvements in lipid profiles and endothelial function, which may help reduce the risk of cardiovascular events in diabetic patients.
• Weight management: Metformin HCI is known to be weight-neutral or may even lead to modest weight loss, making it beneficial for overweight or obese individuals with diabetes.

Dosage and Administration: The dosage of Pozemet 15/500mg Tablet should be individualized based on the patient’s glycemic response and tolerance to therapy. It is usually taken orally with meals to minimize gastrointestinal side effects associated with Metformin HCI. Regular monitoring of blood glucose levels and HbA1c levels is recommended to assess treatment efficacy and adjust the dosage as needed.

Precautions:

• Hypoglycemia: Pozemet 15/500mg Tablet may increase the risk of hypoglycemia, especially when used in combination with insulin or sulfonylureas. Patients should be educated about the signs and symptoms of hypoglycemia and instructed on proper management.
• Lactic acidosis: Metformin HCI, a component of Pozemet 15/500mg Tablet, is associated with a rare but serious side effect called lactic acidosis. Patients should be monitored for signs of lactic acidosis, such as unexplained weakness, muscle pain, respiratory distress, and abdominal discomfort.
• Heart failure: Pioglitazone HCI may exacerbate or precipitate heart failure, particularly in patients with pre-existing cardiac dysfunction. It is contraindicated in patients with New York Heart Association (NYHA) class III or IV heart failure.
• Renal impairment: Metformin HCI should be used with caution in patients with impaired renal function, as it is primarily excreted by the kidneys. Dosage adjustments may be necessary based on estimated glomerular filtration rate (eGFR) levels.

In Summary: Pozemet 15/500mg Tablet is a combination medication used for the management of type 2 diabetes mellitus. It combines Pioglitazone HCI and Metformin HCI to improve glycemic control, increase insulin sensitivity, and reduce cardiovascular risk factors associated with diabetes.

Tags: Pozemet 15/500mg Tablet, Pioglitazone HCI, Metformin HCI, type 2 diabetes mellitus, glycemic control, insulin sensitivity, cardiovascular risk, dosage, precautions